Esofit D 10mg/40mg Capsule SR is a combination pharmaceutical formulation containing Domperidone 10mg and Esomeprazole 40mg, designed for the management of gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating associated with delayed gastric emptying and gastroparesis. Esomeprazole, a proton pump inhibitor, suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, effectively reducing gastric acidity and promoting mucosal healing in acid-related conditions. The sustained-release (SR) formulation ensures a prolonged therapeutic effect, enhancing patient compliance by maintaining consistent plasma drug levels. Esofit D is indicated for the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis, peptic ulcer disease, and other acid-related disorders accompanied by dyspeptic symptoms. It is also beneficial in managing nausea and vomiting associated with delayed gastric emptying. The combination therapy addresses both acid suppression and motility enhancement, offering symptomatic relief and improved quality of life. Contraindications include hypersensitivity to any component, and caution is advised in patients with underlying cardiac conditions due to Domperidone’s potential to prolong QT interval. Administration should follow medical guidance to optimize efficacy and minimize adverse effects.